Recent Updates
Recently added Catalysts

rhIGF-1/rhIGFBP-3

Phase 2

Retinopathy of Prematurity (ROP) | Small molecule | Ophthalmology |Takeda Pharmaceutical Company Limited|Last Updated: May 18, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDDMC
Total Trials1
Total Enrollment76

FDA Designations

No designations recorded

Clinical trial landscape

rhIGF-1/rhIGFBP-3 · 1 trial · 1 indication

Phase 2 1
NCT02386839Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)Retinopathy of Prematurity (ROP)
COMPLETED76 Analytics
PHASE2COMPLETED
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
Retinopathy of Prematurity (ROP)Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected Age (CA)
At 6 Months CA

Standard age-appropriate methods were used to assess visual acuity (how well a participant sees at different distances) with teller acuity cards, LEA symbols test and Charts. It was categorized as following: normal (measurable acuity \>= 20/40 or \>= 15 cycles/degree); below normal (20/200 \<= measurable acuity \< 20/40 or 3 cycles/degree \<= measurable acuity \< 15 cycles/degree); poor (measurable acuity \<= 20/200 or \<= 3 cycles/degree). Corrected Age (weeks) was defined as Chronological Age (weeks) - 40 + Gestational Age (weeks) in this study.

Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 12 Months CA
At 12 Months CA

Standard age-appropriate methods were used to assess visual acuity (how well a participant sees at different distances) with teller acuity cards, LEA symbols test and Charts. It was categorized as following: normal (measurable acuity \>= 20/40 or \>= 15 cycles/degree); below normal (20/200 \<= measurable acuity \< 20/40 or 3 cycles/degree \<= measurable acuity \< 15 cycles/degree); poor (measurable acuity \<= 20/200 or \<= 3 cycles/degree). Corrected Age (weeks) was defined as Chronological Age (weeks) - 40 + Gestational Age (weeks) in this study.

Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 20 Months CA
At 20 Months CA

Standard age-appropriate methods were used to assess visual acuity (how well a participant sees at different distances) with teller acuity cards, LEA symbols test and Charts. It was categorized as following: normal (measurable acuity \>= 20/40 or \>= 15 cycles/degree); below normal (20/200 \<= measurable acuity \< 20/40 or 3 cycles/degree \<= measurable acuity \< 15 cycles/degree); poor (measurable acuity \<= 20/200 or \<= 3 cycles/degree). Corrected Age (weeks) was defined as Chronological Age (weeks) - 40 + Gestational Age (weeks) in this study.

Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 24 Months CA
At 24 Months CA

Standard age-appropriate methods were used to assess visual acuity (how well a participant sees at different distances) with teller acuity cards, LEA symbols test and Charts. It was categorized as following: normal (measurable acuity \>= 20/40 or \>= 15 cycles/degree); below normal (20/200 \<= measurable acuity \< 20/40 or 3 cycles/degree \<= measurable acuity \< 15 cycles/degree); poor (measurable acuity \<= 20/200 or \<= 3 cycles/degree). Corrected Age (weeks) was defined as Chronological Age (weeks) - 40 + Gestational Age (weeks) in this study.

Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 4.75 Years CA
At 4.75 Years CA

Standard age-appropriate methods were used to assess visual acuity (how well a participant sees at different distances) with teller acuity cards, LEA symbols test and Charts. It was categorized as following: normal (measurable acuity \>= 20/40 or \>= 15 cycles/degree); below normal (20/200 \<= measurable acuity \< 20/40 or 3 cycles/degree \<= measurable acuity \< 15 cycles/degree); poor (measurable acuity \<= 20/200 or \<= 3 cycles/degree). Corrected Age (weeks) was defined as Chronological Age (weeks) - 40 + Gestational Age (weeks) in this study.

Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 5 Years CA
At 5 Years CA

Standard age-appropriate methods were used to assess visual acuity (how well a participant sees at different distances) with teller acuity cards, LEA symbols test and Charts. It was categorized as following: normal (measurable acuity \>= 20/40 or \>= 15 cycles/degree); below normal (20/200 \<= measurable acuity \< 20/40 or 3 cycles/degree \<= measurable acuity \< 15 cycles/degree); poor (measurable acuity \<= 20/200 or \<= 3 cycles/degree). Corrected Age (weeks) was defined as Chronological Age (weeks) - 40 + Gestational Age (weeks) in this study.

Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 12 Months CA
At 12 Months CA

Ocular alignment was assessed in primary gaze by comparing the position of the corneal light reflection in left eye and right eye (corneal light reflection assessment). Presence or absence of strabismus was recorded in primary gaze and in as many of the 9 positions of gaze as feasible with the cover test assessment of refixation movement. Extraocular muscle over action or deficiency was recorded. Ocular motility referred to eye movements governed by the 6 extraocular muscles in each eye. It was assessed by examiner observation of the participants ability to abduct, adduct, supra, and inferoduct each eye. Ocular alignment and motility included the presence or absence of strabismus (classified as Esotropia \[inward turn of the eye\], Exotropia \[outward turn of the eye\], Hypertropia \[upward turn of the eye\], Hypotropia \[downward turn of the eye\]) was recorded. Number of participants with combined data for ocular alignment and oculomotor examination (motility) at 12 months CA were reported.

Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 24 Months CA
At 24 Months CA

Ocular alignment was assessed in primary gaze by comparing the position of the corneal light reflection in left eye and right eye (corneal light reflection assessment). Presence or absence of strabismus was recorded in primary gaze and in as many of the 9 positions of gaze as feasible with the cover test assessment of refixation movement. Extraocular muscle over action or deficiency was recorded. Ocular motility referred to eye movements governed by the 6 extraocular muscles in each eye. It was assessed by examiner observation of the participants ability to abduct, adduct, supra, and inferoduct each eye. Ocular alignment and motility included the presence or absence of strabismus (classified as Esotropia, Exotropia, Hypertropia, Hypotropia) was recorded. Number of participants with combined data for ocular alignment and oculomotor examination (motility) assessed by corneal light reflex and by the cover test at 24 months CA were reported.

Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 5-Years CA
At 5 Years CA

Ocular alignment was assessed in primary gaze by comparing the position of the corneal light reflection in left eye and right eye (corneal light reflection assessment). Presence or absence of strabismus was recorded in primary gaze and in as many of the 9 positions of gaze as feasible with the cover test assessment of refixation movement. Extraocular muscle over action or deficiency was recorded. Ocular motility referred to eye movements governed by the 6 extraocular muscles in each eye. It was assessed by examiner observation of the participants ability to abduct, adduct, supra, and inferoduct each eye. Ocular alignment and motility included the presence or absence of strabismus (classified as Esotropia, Exotropia, Hypertropia, Hypotropia) was recorded. Number of participants with combined data for ocular alignment and oculomotor examination (motility) assessed by corneal light reflex and by the cover test at 5-Years CA were reported.

Number of Participants With Nystagmus at 12 Months CA
At 12 Months CA

Nystagmus was observed during the ocular alignment assessments. Presence and absence of nystagmus was reported at 12 Months CA.

Number of Participants With Nystagmus at 24 Months CA
At 24 Months CA

Nystagmus was observed during the ocular alignment assessments. Presence and absence of nystagmus was reported at 24 Months CA.

Number of Participants With Nystagmus at 5 Years CA
At 5 Years CA

Nystagmus was observed during the ocular alignment assessments. Presence and absence of nystagmus was reported at 5 Years CA.

Refraction With Cycloplegia as Assessed by Retinoscopy at 6 Months CA
At 6 Months CA

Refraction was a measure of the lens power required for a focused image on the retina. Refraction with cycloplegia was measured and recorded in diopters for each eye individually (left eye and right eye). Refraction with cycloplegia performed as part of the corrective lens determination procedure included measurements of sphere, cylinder, axis, and prism for each individual eye (left eye and right eye). For sphere, the negative values are summarized as 'nearsighted', and the positive values (including sphere of 0.00) are summarized as 'farsighted'.

Refraction With Cycloplegia as Assessed by Retinoscopy at 12 Month CA
At 12 Months CA

Refraction was a measure of the lens power required for a focused image on the retina. Refraction with cycloplegia was measured and recorded in diopters for each eye individually (left eye and right eye). Refraction with cycloplegia performed as part of the corrective lens determination procedure included measurements of sphere, cylinder, axis, and prism for each individual eye (left eye and right eye). For sphere, the negative values are summarized as 'nearsighted', and the positive values (including sphere of 0.00) are summarized as 'farsighted'.

Refraction With Cycloplegia as Assessed by Retinoscopy at 20 Month CA
At 20 Months CA

Refraction was a measure of the lens power required for a focused image on the retina. Refraction with cycloplegia was measured and recorded in diopters for each eye individually (left eye and right eye). Refraction with cycloplegia performed as part of the corrective lens determination procedure included measurements of sphere, cylinder, axis, and prism for each individual eye (left eye and right eye). For sphere, the negative values are summarized as 'nearsighted', and the positive values (including sphere of 0.00) are summarized as 'farsighted'.

Refraction With Cycloplegia as Assessed by Retinoscopy at 4.75 Years CA
At 4.75 Years CA

Refraction was a measure of the lens power required for a focused image on the retina. Refraction with cycloplegia was measured and recorded in diopters for each eye individually (left eye and right eye). Refraction with cycloplegia performed as part of the corrective lens determination procedure included measurements of sphere, cylinder, axis, and prism for each individual eye (left eye and right eye). For sphere, the negative values are summarized as 'nearsighted', and the positive values (including sphere of 0.00) are summarized as 'farsighted'.

Number of Participants With Stereoacuity as Assessed With the Lang Stereotest At 5 Years CA
At 5 Years CA

Stereoacuity, a measure of depth perception, was assessed using the Lang Stereotest. Number of participants with presence and absence of stereopsis (the ability to perceive depth and 3-dimensional structure) was reported.

Number of Participants With Adverse Events (AEs)
From start of study up to end of study (up to 6.5 years)

An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.

Secondary Endpoints

Change From Baseline in Body Weight Z-score
Baseline, 6 Months CA, 12 Months CA, 24 Months CA and 5 Years CA
Change From Baseline in Height Z-score
Baseline, 6 Months CA, 12 Month CA, 24 Months CA and 5 Years CA
Change From Baseline in Head Circumference Z-score
Baseline, 6 Months CA, 12 Months CA and 24 Months CA
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Antecedent Standard of CareEXPERIMENTALParticipants who were treated with standard neonatal care in study ROPP-2008-01 (NCT01096784) were enrolled in this group for assessment of rhIGF-1/rhIGFBP-3 long-term efficacy and safety outcomes.
Antecedent rhIGF-1/rhIGFBP-3EXPERIMENTALParticipants who were treated with rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) were enrolled in this group for assessment of rhIGF-1/rhIGFBP-3 long-term efficacy and safety outcomes.

Interventions

NameTypeDescription
rhIGF-1/rhIGFBP-3DRUGParticipants who received "rhIGF-1/rhIGFBP-3" in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study.
Unlock Study Design Details

Eligibility Criteria

Age Range40 Weeks to 108 Weeks
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * Participant was randomized in Study ROPP-2008-01 Section D (NCT01096784). * Participants parent or legally authorized representative(s) must provide written informed consent prior to performing any study-related activities. Study-related activities are any procedures that woul...

Countries:United StatesItalyNetherlandsPolandSwedenUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about rhIGF-1/rhIGFBP-3

What is rhIGF-1/rhIGFBP-3 used for?

rhIGF-1/rhIGFBP-3 is an investigational small molecule being developed for Retinopathy of Prematurity (ROP), a condition affecting the retina of premature infants. It is currently in Phase 2 clinical development and is not approved by the FDA.

Who makes rhIGF-1/rhIGFBP-3?

rhIGF-1/rhIGFBP-3 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Retinopathy of Prematurity.

What phase is rhIGF-1/rhIGFBP-3 in?

rhIGF-1/rhIGFBP-3 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is not currently in active trials.

What clinical trials is rhIGF-1/rhIGFBP-3 in?

rhIGF-1/rhIGFBP-3 has one completed Phase 2 trial, NCT02386839, which evaluated long-term safety and efficacy in children previously enrolled in a prevention study for Retinopathy of Prematurity. The trial enrolled 76 participants across the United States, Italy, Netherlands, Poland, Sweden, and the United Kingdom.

Is rhIGF-1/rhIGFBP-3 the same as other names?

rhIGF-1/rhIGFBP-3 is also known as recombinant human insulin-like growth factor-1 bound to recombinant human insulin-like growth factor binding protein-3. This combination is being studied for its potential role in preventing Retinopathy of Prematurity in premature infants.